Systemic atrioventricular valve (SAVV) surgery remains a “valuable option” for the management of patients with congenitally corrected transposition of the great arteries (ccTGA), with low early mortality and satisfactory long-term outcomes, particularly in those with systemic ventricular ejection fraction (SVEF) of 40% or greater, reports a new retrospective analysis of patient data.